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Abstract
Background: Biomarkers predicting tuberculosis treatment response and cure would facilitate drug development. This
study investigated expression patterns of the co-stimulation molecule NKG2D in human tuberculosis and treatment to
determine its potential usefulness as a host biomarker of tuberculosis drug efficacy.
Methods: Tuberculosis patients (n = 26) were recruited in Lahore, Pakistan, at diagnosis and followed up during treatment.
Household contacts (n = 24) were also recruited. NKG2D expression was measured by qRT-PCR in RNA samples both ex vivo
and following overnight mycobacterial stimulation in vitro. Protein expression of NKG2D and granzyme B was measured by
flow cytometry.
Results: NKG2D expression in newly diagnosed tuberculosis patients was similar to household contacts in ex vivo RNA, but
was higher following in vitro stimulation. The NKG2D expression was dramatically reduced by intensive phase
chemotherapy, in both ex vivo blood RNA and CD8+ T cell protein expression, but then reverted to higher levels after
the continuation phase in successfully treated patients.
Conclusion: The changes in NKG2D expression through successful treatment reflect modulation of the peripheral cytotoxic
T cell response. This likely reflects firstly in vivo stimulation by live Mycobacterium tuberculosis, followed by the response to
dead bacilli, antigen-release and finally immunopathology resolution. Such changes in host peripheral gene expression,
alongside clinical and microbiological indices, could be developed into a biosignature of tuberculosis drug-induced cure to
be used in future clinical trials.
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Introduction
Tuberculosis (TB) remains a major pandemic health problem.
In 2011, 8.7 million new cases were reported worldwide, of which
1.1 million cases were seen in HIV positive individuals, and 1.4
million people died [1]. Co-infection with HIV/AIDS and the
emergence of drug resistant strains have made improved TB
control an urgent necessity. Most immunocompetent people
mount an effective immune response against the aetiological agent
Mycobacterium tuberculosis, such that infection is controlled in a latent
asymptomatic form in 90% of individuals [2].
TB treatment is long, leading to lack of adherence, acquired
drug resistance and a 5% risk of relapse [3,4]. There is no way of
knowing if lung sterilization is achieved at an earlier time point;
therefore biomarkers capable of predicting treatment efficacy/
outcome are needed to aid clinical management [5,6]. Biomarkers
that can accelerate the drug developmental pipeline are also
urgently needed, as current clinical trials use TB-relapse in a two
year follow-up period to measure drug efficacy [7], although new
recommendations suggest a shorter period would be sufficient [8].
CD8+ T cells play a pivotal role in TB immunity, particularly at
later stages of infection and when bacillary burden is high [9–11].
There is a functional overlap between CD4+ and CD8+ T cells:
both produce cytokines such as TNF-a and IFN-c to activate M.
tuberculosis infected dendritic cells and macrophages, however
CD8+ T cells exhibit strong cyolytic activity enabling them to kill
infected phagocytic cells: this activity has been observed in both
mouse [12–14] and human [15–17] tuberculosis.
The NKG2D receptor is a member of the type II C-type lectin-
like family of transmembrane proteins, and plays an essential role
in both innate and adaptive immunity [18]. NKG2D is expressed
as a homodimer on NK cells, cd T cells, some CD4+ and CD8+ T
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cells [19]. NKG2D lacks signaling domains on its short
intracellular tail and uses an adaptor molecule, DNAX-Activation
Protein 10 (DAP10), to relay signals inside cells [19]. NKG2D
binds a wide range of ligands that differ considerably in sequence,
domain structure and affinity for the receptor [20] [21]. In
humans, these ligands can be broadly divided into two families:
major histocompatibility complex class I chain-related (MIC) and
UL-16 binding proteins (ULBPS). The former family comprises
highly polymorphic MICA and MICB, the expression of which are
significantly upregulated on stressed, malignant and infected cells
[22], including infection with M. tuberculosis [23].
In NK cells, NKG2D is a ‘‘master-switch’’ of activation that
cannot be overcome by inhibitory signals. However, in T cells,
NKG2D acts as a co-stimulatory receptor until a high activation
status is reached, influenced by cytokine action, that enables it to
act as an activation receptor and bypassing the conventional TCR-
CD28 stimulation pathway [19]. Silencing of NKG2D and its
adaptor molecules DAP10 and 12 by RNA interference leads to
reduced cytotoxic activity of human NK and CD8+ T cells [24].
CD28 and NKG2D have overlapping but not identical functions.
In mice, CD28 enhances CD8+ T cell function and survival
whereas NKG2D only does the former [25]. In a tissue specific
context, NKG2D expression is more important on antigen-specific
lung resident effector T cells compared to memory ones [26]. The
majority of studies have shown that NKG2D can act as a co-
stimulatory molecule in its own right [27,28], however Ehrlich et al
found the opposite result i.e. NKG2D requires other co-factors
such as CD28 to trigger CD8+ T cell proliferation, cytokine
production and cytotoxicity in both murine and human cells [29].
NKG2D expression regulation is multi-layered; availability of
DAP10, differential regulation by cytokines and chronic exposure
to soluble or membrane bound NKG2D ligands control this
pathway. This regulation may be awry in TB, due to its chronicity
and the aetiological agent, M.tuberculosis, which has devised
numerous immune evasion strategies. Some studies have shown
that NKG2D may play a role in TB. Blocking NKG2D leads to
inhibition of M. tuberculosis-specific CD8+ T cells in vitro [30] while
NKG2D expression is up-regulated by mycobacterial stimulation
in vitro [31]. Expression patterns of NKG2D have not been
investigated in latent M. tuberculosis infection, active TB disease or
during TB treatment in humans, despite its up-regulation upon
mycobacterial stimulation in vitro.
The aim of this study was to determine the potential use of
NKG2D as a host biomarker capable of predicting treatment
response in human TB: this was achieved by measuring NKG2D
mRNA and protein expression in healthy donors in the United
Kingdom and in household contacts and newly diagnosed TB
patients recruited in Lahore, Pakistan. We hypothesised that as
NKG2D is involved in killing M. tuberculosis-infected cells, it would
be more highly expressed in TB patients at diagnosis compared
with household contacts, with a subsequent reduction in expres-
sion during successful TB treatment.
Materials and Methods
Ethics Statement
The study was approved by the LSHTM (study number 5459)
and Gulab Devi Hospital Ethics committees. Informed written
consent was obtained from all subjects for taking blood samples,
analysis of mycobacterial immune responses and sample storage.
The study was conducted according to the Declaration of Helsinki
principles.
Subject Recruitment and Venous Blood Sample
Collection
In preliminary experiments, blood samples from healthy BCG-
vaccinated donors were obtained from staff and students recruited
at the London School of Hygiene & Tropical Medicine (LSHTM),
U.K. Donors were BCG-vaccinated in adolescence, with blood
samples collected more than ten years post-vaccination.
Subsequently twenty-six first-episode pulmonary tuberculosis
inpatients were recruited at diagnosis into a longitudinal study,
conducted at Gulab Devi Chest Hospital, Lahore, Pakistan in
2009/2010, and were treated according to prevailing Pakistan
National Tuberculosis Program guidelines (2HRZE/6HE). Ve-
nous blood samples (10–30 ml) were obtained at diagnosis prior to
treatment initiation, at the end of the two-month intensive phase
and after completion of treatment (eight months). The inclusion
criteria for patients included an age limit of 20–70 years, being
HIV-negative and non-diabetic, haemoglobin level of $8g/dL
and sputum smear positive and culture positive by solid culture on
LJ slopes. Treatment outcomes were ascertained from patient
records. Where possible, for each TB patient, blood samples were
obtained from one adult household contact, defined as living in the
same room when the TB patient was diagnosed (Table 1).
Table 1. Characteristics of tuberculosis patients and household contacts.
TB patients (n =26) Household contacts (n =24)
Age, years: median [range] 38 [20–60] 40 [20–65]
Gender: n, (% ) female 5 (20%) 15 (62%)
Classification of TB on CXR: Moderate = 23, Mild = 3 N/A
Treatment Outcome Cured1 = 24, Died = 2
Study follow-up sample provided2 2months = 18, 8months = 6 N/A
Relationship to TB patient N/A Spouse = 5 Parent = 10 Child = 2
Sibling = 7
Infection status of household contact: n (%) N/A Latently infected3 = 13 (54%),
Uninfected4 = 11 (46%)
1Cured defined as sputum smear and culture negative at 8 months, with no clinical symptoms.
2The loss-to-follow-up at 2 months was due to early hospital discharge and at 8 months was due to severe flooding in Pakistan in 2010.
3Latently infected defined as IGRA-positive, normal chest X-ray and sputum smear negative.
4Not infected defined as IGRA-negative, normal chest X-ray and sputum smear negative. N/A not applicable.
doi:10.1371/journal.pone.0070063.t001
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QuantiFERONH-TB Gold (Cellestis, Ltd, Carnegie, Australia) was
used in conjunction with lack of clinical symptoms or radiological
evidence of TB to categorise the healthy household contacts as
latently infected or not infected with M. tuberculosis. All the
household contacts remained healthy and did not develop TB
during a 1-year follow-up period after recruitment. Comparisons
between TB patients and control subjects were with these
household contact groups. For each patient or contact sample,
3 ml blood was collected into Tempus RNA tubes (Applied
Biosystems) and stabilised by shaking vigorously for 10 seconds
prior to freezing at280uC. PBMC were isolated and stimulated
immediately as described below, or frozen for downstream flow
cytometry using cryoprotective reagent consisting of 10% DMSO
(Sigma-Aldrich, Dorset, U.K.) in human AB serum-supplemented
growth medium.
Cell Isolation and Stimulation
Peripheral Blood Mononuclear Cells (PBMC) were separated
from whole blood using density centrifugation over Ficoll-
Figure 1. Regulation of NKG2D and DAP10 mRNA following mycobacterial stimulation in vitro. CD4+ and CD8+ T cells were isolated from
ten healthy BCG-vaccinated donors after 7 days of PBMC stimulation with live M. tuberculosis H37Rv, on ten separate occasions. NKG2D (A) and
DAP10 (B) mRNA expression levels in each T cell subset were determined by qRT-PCR. Data are normalised against the HPRT housekeeping gene, with
the mean of duplicate technical replicates shown. (C) Diluted whole blood cultures from five healthy donors were incubated on five separate
occasions with live M. bovis BCG in the absence or presence of IL-2 for the time indicated. NKG2D mRNA expression was determined for each sample
in duplicate by qRT-PCR and is shown normalised against HPRT and normalised against the unstimulated control at each time point, with mean and
standard error of the mean for the five donors shown. *P,0.05 compared to the medium control cultures. (D) Diluted whole blood cultures from nine
BCG-vaccinated donors were incubated with live M. bovis BCG or live M. tuberculosis for six days in three separate experiments. NKG2D mRNA
expression is shown normalised against HPRT mRNA expression, with the mean and standard error of the mean of the nine donors shown. Statistical
comparisons were performed using the Wilcoxon signed rank test for paired data.
doi:10.1371/journal.pone.0070063.g001
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Histopaque 1077 (Sigma-Aldrich, Dorset, U.K.). For stimulation
with live M. tuberculosis, PBMC from healthy BCG-vaccinated
donors were cultured in L-glutamine supplemented RPMI-1640
(Invitrogen, U.K.) at 1x106/ ml with M. tuberculosis H37Rv at a
multiplicity of infection (MOI) of 1:1 (bacilli: monocyte) for 7 days.
CD4+ and CD8+ T cells were isolated from the PBMC cultures
using Dynabeads (Dynal Biotech, Wirral, U.K.) and lysed and
frozen at280uC in RNAzol B (Biogenesis, Dorset, U.K.). Ten-fold
diluted whole blood from BCG-vaccinated donors was incubated
in supplemented RPMI-1640 with live M. bovis BCG or M.
tuberculosis H37Rv at 1:1 MOI, assuming peripheral blood contains
4x105 monocytes/ml, for 7 days and the cell layer was lysed and
frozen at280uC in mRNA Stabilization reagent (Roche Applied
Science). PBMC from TB patients and household contacts at
2x106/ ml were cultured alone or stimulated for 16 hours with live
M. bovis BCG at 10:1 or 1:1 MOI or immobilized 2 mg/ml anti-
Figure 2. TB patient recruitment and follow-up. Sputum smear positive pulmonary TB patients were recruited in Lahore, Pakistan, from the
inpatient department at Gulab Devi chest hospital. Blood samples were collected at diagnosis and where possible after the intensive treatment phase
and after the full treatment phase: study follow-up success is shown. The number of patients who were sputum smear positive after the intensive
phase is indicated. Apart from the two patients who died, all patients were sputum and culture negative at the end of treatment and classified as
cured according to hospital records. Healthy household contacts of the TB patients were also recruited, and all had normal chest X-rays, no symptoms
and were sputum smear negative.
doi:10.1371/journal.pone.0070063.g002
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CD3 (Mabtech, Stockholm, Sweden) in supplemented RPMI-
1640. Cell pellets were lysed and frozen at280uC in RLT buffer
(RNeasy kit; Qiagen, West Sussex, U.K.).
RNA Extraction and qRT-PCR
RNA was extracted using the RNAzol protocol, the Roche
mRNA isolation kit, Qiagen RNeasy extraction kit or the Tempus
Spin extraction kit (Applied Biosystems) as appropriate for the
sample, following manufacturers’ instructions. Any potentially
contaminating DNA was removed by DNAse treatment, using on-
column DNAse (Qiagen) where possible or alternatively Ambion
TURBO DNA-freeTM (Invitrogen). RNA quality was checked using
a 2100 Bioanalyzer (Agilent Technologies) and quantified using
the Ribogreen assay (Invitrogen).
Equivalent amounts of mRNA from each sample were reverse
transcribed using oligo-dT primers and Superscript III (Invitrogen)
in 20 ml reactions, and the reaction mix was then diluted to 100 ml
prior to use. Quantitative RT-PCR (qRT-PCR) was performed
with 5 ml cDNA using either an ABI Prism 7000 or 7500 Fast
machine, and Applied Biosystems SYBRGreen reagents. Primer
sequences were kindly provided by Dr Martin Holland for HPRT
[32]. Other primers were designed using Primer3 software [33]
and gene-specificity checked by nucleotide BLAST [34]: qRT-
PCR primer sequence were NKG2D-Sense (S):
CTGGTGAAGTCATATCATTGGATGG; NKG2D-Anti-sense
(A): AGAATGGAGCCATCTTCCCACT; DAP10-S:
CTGCCAGACCCCAGTCCAC; DAP10-A: TGGGAG-
CAAAAGCAGGAAGA; HPRT–S: GGCAGTATAATCCAAA-
GATGGTCA; HPRT–A: GTCTGGCTTATATCCAA-
CACTTCGT; Cyclophilin A-S:
GCTGGACCCAACACAAATGG; Cyclophilin A-A:
TTGCCAAACACCACATGCTT.
Flow Cytometry
Frozen PBMC were thawed by drop-wise addition of cold
RPMI-1640 medium followed by centrifugation and two washes
with RPMI-1640 medium prior to cell counting. The PBMCs
were incubated overnight in growth medium at 37uC/5% CO2,
with Brefeldin A (Becton Dickinson-BD) included for the last three
hours. Single stain compensation tubes and fluorescence minus
one (FMO) controls were used. One million PBMCs per tube were
stained with anti-CD3 (PERCP-Cy 5.5, clone OKT3: e-Biosci-
ence), anti-CD8 (FITC, clone OKT8:(e-Bioscience) and anti-
NKG2D (PE, clone 1D11:BD) prior to adding fixation and
permeabilisation solutions (BD). Intracellular staining was per-
formed with a pre-titrated amount of anti-Granzyme B (Alexa-
Fluor 647, clone GB-11: BD). Paraformaldehyde/PBS (10%)
(Sigma) was added to the samples prior to running on a FACS
Calibur 4CA E5180 (BD) under Category 3 conditions. Data were
analysed using FlowJo (v7.6). Lymphocytes were gated using
forward versus side scatter. Dead cells were excluded using Live/
dead staining (Invitrogen).
Data Analysis
All data were analysed using non-parametric tests in GraphPad
Prism v5: the Wilcoxon signed rank test was used for paired data
and the Wilcoxon rank sum test (Mann-Whitney test) for unpaired
data. Expression changes within the successfully cured patient
group were analysed separately from those who died, so that
expression changes which might potentially correlate with
treatment-response could be identified. Prior to patient recruit-
ment, a sample size calculation based on pilot data indicated that a
cohort of 23 patients and 23 contacts would have 90% power to
detect a difference between TB patients and contacts of 2.9-fold
(assuming standard deviation 3 in each group) with a type I error
of 5%.
Results
Expression of NKG2D, but not DAP10, mRNA is up-
regulated by CD8+ T Cells Following Mycobacterial
Stimulation
In a DNA-array study [31] we found that NKG2D mRNA
expression was enhanced on CD8+ T cells compared to CD4+ T
cells. Here, PBMC from ten BCG-vaccinated biologically inde-
pendent donors were stimulated for 7 days with live M. tuberculosis,
the CD4+ and CD8+ T cells were isolated and expression of
NKG2D was assessed. NKG2D expression was highly elevated in
CD8+ T cells (p = 0.002) (Figure. 1A). In contrast, there was no
consistent expression pattern between CD4+ and CD8+ T cells for
DAP10, which transduces NKG2D signals in CD8+ T cells
(p = 0.13) (Figure. 1B). Thus NKG2D mRNA expression appears
to be the limiting factor in NKG2D-DAP10 regulation in CD8+ T
cells following M. tuberculosis stimulation. To determine whether
NKG2D expression could be detected in whole blood, diluted
whole blood cultures from five healthy individuals were incubated
with live M. bovis BCG, and the level of NKG2D mRNA increased
steadily throughout a 2-week incubation period (Figure 1C). This
was enhanced by inclusion of IL-2, possibly by promoting cell
survival or proliferation, or via a direct effect on NKG2D
expression [19]. Similar levels of NKG2D expression were
observed following stimulation with either M. tuberculosis or M.
bovis BCG in diluted whole blood cultures (Figure 1D). These
results showed that diluted whole blood cultures and M. bovis BCG
stimulation could be a useful method for measuring changes in
NKG2D expression in a more clinical setting.
NKG2D ex vivo Blood Gene Expression is Unaltered
During Active TB Disease but Changes with Successful
Chemotherapy
As NKG2D was expressed by healthy donors’ CD8+ T cells
following mycobacterial stimulation in vitro, we hypothesized that
NKG2D gene expression would be elevated in active TB patients
compared to contacts due to in vivo mycobacterial exposure. For
this purpose, 26 pulmonary TB patients were recruited in Pakistan
at the start of TB treatment, of whom 18 (69%) and 6 (23%) were
followed up at 2 months and 8 months respectively (Table 1 and
Figure 2). Twenty-four patients were cured at the end of
treatment, all of whom remained disease free in the subsequent
12 month period. Two patients died during the continuation
phase: these two patients remained sputum and culture positive
after two months of treatment, and verbal autopsy indicated their
likely cause of death was TB. At the same time as TB patient
recruitment, 24 household contacts were recruited, of whom 13
(54%) were classified as latently infected and 11 (46%) as
uninfected, based on their IFNc responses in the QuantiFER-
ONH-TB Gold assay.
Contrary to expectation, there was no difference in NKG2D
gene expression between untreated TB patients, latently infected
and uninfected contacts at diagnosis, although a trend towards
reduced expression in patients compared to uninfected contacts
was observed (Figure 3A). There was considerable heterogeneity
within the latently-infected group, possibly due to subjects
possessing different degrees of subclinical infection. Next, we
investigated the effect of anti-TB drug treatment on NKG2D
expression. Among TB patients who were subsequently success-
fully cured, there was a decline in NKG2D mRNA expression
NKG2D Expression Modulation in Human Tuberculosis
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from treatment initiation (median 5.8 arbitrary units) to the end of
the 2-month intensive treatment phase (median 0.6 arbitrary units)
(p = 0.0005) (Figure 3B). There was no apparent reduction in the
NKG2D mRNA expression in the two patients who subsequently
died (Figure 3B). In the six cured patients for whom data were also
available at the end of TB treatment, this decline in NKG2D
mRNA expression was observed in the intensive phase (p = 0.04),
but was followed by an increase (p = 0.04) during the continuation
phase (median at diagnosis 9.4, at 2 months 0.77 and at 8 months
11.6 arbitrary units) (Figure 3C).
Active TB Patients Exhibit Enhanced NKG2D Expression
Following Antigenic re-stimulation in Vitro
As the NKG2D expression in ex vivo blood was modified during
active TB disease and TB chemotherapy, we investigated whether
the NKG2D-mediated cytolytic potential upon antigenic re-
stimulation was altered. PBMC from active TB patients expressed
higher levels of NKG2D mRNA compared to both latently-
infected (p= 0.02) and non-infected (p = 0.03) contacts in response
to live M. bovis BCG stimulation (Figure 4A). Similar responses
were seen for latently-infected and non-infected contacts
(Figure 4A). A small difference between responses in active TB
patients and uninfected contacts was also observed with anti-CD3
stimulation (p= 0.03) (Figure 4A). Among TB patients, we found a
decline in antigen-induced NKG2D mRNA expression during the
intensive phase of chemotherapy, for both M. bovis BCG
(p= 0.002) and anti-CD3 stimulation (p= 0.001), in patients who
were subsequently successfully cured (Figure 4B). There also
appeared to be a reduction in the NKG2D expression following
stimulation in the two patients who died, in contrast to the ex vivo
expression levels (Figure. 4C). For both the M. bovis BCG and anti-
CD3 stimulated samples, samples from the end of successful
treatment showed a trend towards increased NKG2D expression
(Figure. 4D).
NKG2D Protein Expression is down-regulated by
Intensive Phase TB Treatment
As NKG2D mRNA expression was modulated by TB
chemotherapy, we next investigated whether these mRNA
changes were translated into changes in protein expression. No
differences in NKG2D protein expression were found between TB
patients at diagnosis, latently infected contacts and uninfected
contacts in the total lymphocyte gate (not shown), nor in the
CD3+CD8+ cell subset or the CD3- lymphocyte subset which
would have contained NK cells (Figure 5A). The NKG2D protein
expression was decreased during the first 2 months of successful
TB treatment in the CD3+CD8+ T cell compartment (p = 0.0038),
whereas the expression within the non-T cell lymphocyte
compartment was more similar at diagnosis and 2 months
(p = 0.25) (Figure 5B). In contrast, in the two patients who
subsequently died, there was no apparent decrease in the NKG2D
protein expression, in either the CD8+ T cell or the non-T cell
compartments (Figure 5C). Thus the decline in NKG2D protein
expression in the first two months of chemotherapy confirmed the
mRNA expression results.
NKG2D/Granzyme B Protein co-expression Increases with
the Intensive Phase of Treatment
We next investigated NKG2D expression in concert with
Granzyme B expression, to establish whether NKG2D has an
impact on cytotoxicity and degranulation in active TB and during
chemotherapy. No differences were found between NKG2D/
Granzyme B co-expression between TB patients at diagnosis,
Figure 3. NKG2D ex vivo blood gene expression prior to and
during chemotherapy. RNA was extracted from whole blood
Tempus tubes and gene expression investigated by qRT-PCR. (A)
NKG2D expression in ex vivo venous blood from untreated active TB
cases at diagnosis (n = 26), in latently-infected household contacts
(Contacts (+): n = 13) and in uninfected contacts (Contacts (2): n = 11),
all recruited in Lahore, Pakistan. The Wilcoxon ranksum test was used to
compare the clinical groups. (B) NKG2D expression after the end of the
intensive phase in 16 patients who were eventually successfully cured
(closed circles) and in 2 patients who subsequently died (open circles).
(C) NKG2D expression during the entire course of TB chemotherapy in a
different 6 patients, for whom data were available at the end of
treatment. The Wilcoxon signrank test was used to analyse the paired
data in (B) and (C). The lines in the centre of each group represent
medians. NKG2D mRNA expression was determined by qRT-PCR, with
results shown normalised against the housekeeping gene Cyclophilin A.
doi:10.1371/journal.pone.0070063.g003
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latently infected and uninfected contacts, in either the CD3+CD8+
cell subset or the CD3- lymphocyte subset (Figure 6A). NKG2D/
Granzyme B co-expression remained unchanged in CD8+ T cells
after the intensive phase of treatment in successfully cured patients
(p.0.99) (Figure 6B): the two patients who subsequently died did
not fit with this pattern of consistent low level NKG2D/Granzyme
B co-expression. NKG2D/Granzyme B co-expression in the non-
T cell lymphocyte compartment appeared to be higher at the end
of the intensive phase compared with at diagnosis, in both the
cured patients and those who later died (Figure 6C), though
statistical evidence was weak (p= 0.16 for cured patients).
Discussion
We have demonstrated that NKG2D expression was regulated
in a complex, biphasic manner during TB drug treatment in TB
patients. To our knowledge, this is the first study that has
investigated NKG2D gene and protein expression on CD8+
cytotoxic T cells during active TB disease, latent infection and TB
treatment. Contrary to our expectation, the ex vivo NKG2D
mRNA expression and lymphocyte protein expression in blood
was not significantly different in active TB disease compared to
latently-infected or non-infected household contacts at diagnosis.
There was, however, a dramatic reduction in NKG2D expression
within the 2 month intensive treatment phase, and this was
followed by a return to high levels by the end of treatment in
successfully cured patients. There was no modulation of NKG2D
expression in two patients who died during the continuation phase.
NKG2D is expressed by cytotoxic cells, where it is involved in
cytolytic killing [20,35], and it can mediate costimulation for
CD8+ T cells [25], promoting a Tc1 phenotype [36]. In this study,
NKG2D mRNA was highly expressed in CD8+ T cells compared
to CD4+ T cells in healthy donors following stimulation in vitro
with mycobacteria. In contrast, DAP10 mRNA was expressed in
both T cell subsets, indicating that expression of the two protein
subunits of the receptor complex are regulated via different
mechanisms, in accordance with a previous study [37]. The
modulation of NKG2D expression in TB patients with successful
treatment occurred in CD8+ T cells, and to a lesser extent on NK
cells, as determined by flow cytometry. CD8+ T cells are crucially
involved in protection against M. tuberculosis: patients with active
TB disease have fewer circulating terminally-differentiated CD8+
T cells than latently-infected healthy subjects, with a reduction in
the proportion of polyfunctional CD8+ T cells and lower perforin
and IFNc production [38].
Figure 4. NKG2D gene expression at diagnosis and during chemotherapy in in vitro stimulated RNA samples. PBMC were isolated and
stimulated in vitro with M. bovis BCG (MOI 1:1) or anti-CD3 mAb for 16 hours and NKG2D mRNA expression analysed by qRT-PCR. (A) NKG2D mRNA
expression at TB diagnosis in 26 untreated TB patients (P), 13 latently infected contacts (C+) and 11 uninfected contacts (C-). (B) Modulation of NKG2D
mRNA expression during the intensive phase of treatment in 16 successfully cured TB patients. (C) NKG2D mRNA expression following stimulation in
2 patients who subsequently died. (D) NKG2D mRNA expression in a separate group of 6 successfully cured patients throughout the full treatment
course. The line in the centre of the box and whisker plots represents the median whereas the top and bottom lines represent the 75th and 25th
quartile respectively, and whiskers represent minimum and maximum data points. The Wilcoxon ranksum test (A.) and the Wilcoxon signrank test (B)
and (D) were used for statistical analyses of unpaired and paired data respectively.
doi:10.1371/journal.pone.0070063.g004
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Figure 5. NKG2D protein expression during active TB disease
and chemotherapy. Frozen PBMCs were thawed and stained to
analyse NKG2D protein expression. (A) NKG2D protein expression on
CD3+CD8+ T cells and CD3- lymphocytes at diagnosis in 21 TB patients
(P), 8 latently infected contacts (C+) and 6 uninfected contacts (C-). Data
were analysed using the Wilcoxon rank sum test. (B) Modulation of
NKG2D protein expression on CD3+CD8+ T cells and CD3- lymphocytes
with the intensive phase of chemotherapy in successfully cured patients
(n = 13). The graphs are box and whisker plots, as described in Figure 3,
and analysed using the Wilcoxon signed rank test. (C) NKG2D protein
expression in 2 patients who subsequently died.
doi:10.1371/journal.pone.0070063.g005
Figure 6. Modulation of NKG2D/GrzB protein co-expression
during active TB disease and chemotherapy. Frozen PBMCs were
thawed and NKG2D/GrzB co-expression was investigated by flow
cytometry. (A) Percentage of NKG2D GrzB double-positive cells in the
CD3+CD8+ lymphocyte gate or CD3- lymphocyte (NK cell) gate at
diagnosis in TB patients (P: n = 18), latently infected contacts (C+: n = 7)
and uninfected contacts (C-: n = 4). Modulation of NKG2D/GzB co-
expression with the intensive phase of chemotherapy on CD3+CD8+ T
cells (B) or CD3- lymphocytes (NK cells) (C) in patients who were
successfully cured (n = 8) or who subsequently died (n = 2). The graphs
are box and whisker plots, as described in Figure 3. The Wilcoxon
ranksum test (A.) and the Wilcoxon signrank test (B) and (C) were used
for statistical analyses of unpaired and paired data respectively.
doi:10.1371/journal.pone.0070063.g006
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The biphasic nature of the changes in NKG2D expression with
treatment might reflect a combination of altered sequestering of
lymphocytes in the lungs, varying with changes in bacterial burden
and antigen level, together with altered differentiation stages of
circulating lymphocytes and altered general ability to respond to
antigenic stimulation. Overnight stimulation of diluted blood in
vitro, either with live mycobacteria (M. bovis BCG) or anti-CD3
mAb, enhanced NKG2D expression in untreated TB patients,
compared to that in uninfected controls or after two months of
treatment. This could imply that there were more differentiated
effector cells in the blood capable of responding rapidly to
antigenic stimulation. Alternatively, the reduced NKG2D expres-
sion at month 2 of treatment might reflect a loss of a cytotoxic
lymphocyte population, possibly due to cellular exhaustion, which
is later replenished, coinciding with cure and immune restoration.
Although it is possible that the antibiotics themselves had a direct
effect on NKG2D expression, we consider this unlikely as in
previous transcriptomic studies, we and other investigators have
seen no evidence of a direct effect on immune cell gene expression
profiles [39,40]. Furthermore, if the change in gene expression was
due to a non-specific toxic effect, one would also expect it occur in
the two patients who died, but this was not the case. Future studies
will be aimed at testing the direct effects of anti-mycobacterial
treatment on peripheral gene expression, to formally rule out this
possibility.
NKG2D has previously been shown to be upregulated on CD8+
T cells from healthy donors following stimulation with live M.
tuberculosis [31] or M. tuberculosis extract [23]. One study examining
NKG2D expression on NK cells in TB patients found no
difference to that in controls [41], in agreement with the present
study. The potential importance of NKG2D in controlling M.
tuberculosis infection has been demonstrated in mouse models,
whereby CD8+ T cell-mediated cytotoxicity is impaired in mice
deficient for DAP10, the NKG2D signaling adapter molecule [42].
IL-15-deficient mice are highly susceptible to M. tuberculosis, and
this defect is mediated in part by reduced NKG2D expression
[30]. NKG2D expression is also modulated by IL-2, which
increases both NKG2D and DAP-10 expression on murine cells
[19], whereas TGF-b, which is elevated in active human TB
disease but declines with chemotherapy [43,44], down-regulates
NKG2D expression on human CD8+ T and NK cells [45,46].
Thus the altered cytokine milieu in active TB and its modulation
with treatment will affect NKG2D expression.
NKG2D has multiple ligands, which are upregulated on
stressed cells or infected cells in a complex manner [47]. Infection
of monocytes and alveolar macrophages with M. tuberculosis leads
to up-regulation of the ULBP1 ligand, and the NKG2D-ULBP1
interaction mediates NK cell-mediated killing [48]. Interestingly,
cytomegalovirus co-infection can inhibit NKG2D ligand expres-
sion, leading to immune-suppression [49]. Furthermore, binding
of soluble ligands, shed from activated CD4+ T cells, can lead to
down-regulation of NKG2D expression and immune-suppression
[50] and this mechanism may have been involved in the dramatic
down-regulation of NKG2D observed in the intensive therapy
phase of this study. Further studies in larger and diverse ethnic
populations should be performed to validate these findings if
NKG2D is to be useful as a biomarker for TB drug discovery.
Changes in NKG2D in response to TB-treatment in HIV-positive
people should also be determined. It would be particularly
interesting to extend the functional characterization of
CD8+NKG2D+ T cells during TB treatment, to determine their
cytokine production and differentiation state.
Host biomarkers of TB treatment-response would revolutionize
clinical trials of new drugs, by allowing sensitive measurement of
drug efficacy early after treatment initiation and without reliance
on microbiological assays or a 2-year relapse rate [6]. We have
shown here that NKG2D expression is greatly reduced in
peripheral blood during the intensive phase of successful TB
treatment. Thus changes in peripheral NKG2D expression might
be a useful contribution to a TB drug-efficacy biosignature in
conjunction with other gene expression [40], secreted immune
mediators and clinical parameters of treatment response. To be
useful in TB drug development, potentially as a surrogate endpoint
for the 2-year relapse rate in clinical trials, a TB drug-efficacy
biosignature would need to be tested and validated in surrogate
marker clinical trials, possibly alongside drug candidate clinical
trials to improve feasibility and reduce cost. Ultimately, a TB
drug-efficacy surrogate marker biosignature would dramatically
reduce the cost of TB drug and regimen clinical trials, allowing
earlier decision making and potentially the licensing of more
compounds.
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